Original Article
MiR-98 inhibits malignant progression via targeting MTDH in squamous cell carcinoma of the head and neck

Haolei Tan1,2,3, Gangcai Zhu4, Li She1,2, Ming Wei1,2, Yuyun Wang1,2, Leiming Pi1,2, Changhan Chen1,2, Diekou Zhang1,2, Pingqing Tan3, Jie Chen3, Donghai Huang1,2, Yongquan Tian1,2, Yong Liu1,2, Xin Zhang1,2

1Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha 410008, Hunan, People’s Republic of China; 2Otolaryngology Major Disease Research Key Laboratory of Hunan Province, 87 Xiangya Road, Changsha 410008, Hunan, People’s Republic of China; 3Department of Head and Neck Surgery, Hunan Cancer Hospital, The Affiliated Tumor Hospital of Xiangya Medical School, Central South University, 283 Tongzipo Road, Changsha 410013, Hunan, People’s Republic of China; 4Department of Otolaryngology Head and Neck Surgery, The Second Xiangya Hospital, Central South University, 139 Renmin Road, Changsha 410011, Hunan, People’s Republic of China

Received November 2, 2017; Accepted November 14, 2017; Epub December 1, 2017; Published December 15, 2017

Abstract: Purpose: MicroRNAs function through regulating specific target mRNA expression and then participate in the development and progression of diverse human cancers. MiR-98 shows aberrant expression and dysfunction in tumors. However, its clinical significance and exact role in squamous cell carcinoma of the head and neck (SCCHN) remain elusive. Methods: MiR-98 expression was examined by qRT-PCR and correlated with clinicopathological variables and prognosis in SCCHN patients. Effects of miR-98 on epithelial-mesenchymal transition (EMT) and the malignant phenotypes of SCCHN were studied. Finally, the role of target gene metadherin (MTDH) in miR-98 mediated effects were assayed. Results: Our results demonstrated that miR-98, as an endogenous inhibitor of MTDH via directly binding to its 3’-untranslated region (UTR) region, decreased significantly in SCCHN tissues. Decreased miR-98 expression was negatively correlated with T classification, clinical stage, lymph node metastasis and a shorter survival status in SCCHN patients. Loss-of-function and gain-of-function analyses confirmed that miR-98 inhibited cell proliferation, migration and invasion of SCCHN cells in vitro. Moreover, miR-98 repression led to increased MTDH expression and induced EMT alteration. Importantly, ectopic expression of MTDH partially reversed the effects caused by miR-98 overexpression. Conclusions: Our study identifies that miR-98 serves as a suppressor in SCCHN progression via targeting oncogene MTDH.

Keywords: Squamous cell carcinoma of the head and neck, metastasis, MicroRNA-98, MTDH, prognosis

Introduction

Squamous cell carcinoma of the head and neck (SCCHN) is an aggressive malignancy that originates from the nasal cavities, paranasal sinuses, oral cavity, nasopharynx, oropharynx, hypopharynx and larynx. Despite multimodal therapies including surgery, radiotherapy and chemotherapy having been applied in clinical settings for decades, the quality of life and survival rate in patients with SCCHN are far from satisfactory [1]. Mounting evidence suggests that cervical lymph node metastasis accounts for the frustrating prognosis in patients with SCCHN [1]. Therefore, it is urgent and necessary to clarify the mechanisms underlying metastasis [7], which will benefit the future surveillance and target therapy in patients with SCCHN.

MTDH, abbreviation of metadherin, also known as astrocyte elevated gene-1 (AEG-1) and lyric, is a novel oncogene that plays a crucial role in various human malignancies, including prostate carcinoma [28], breast carcinoma [10], non-small cell lung cancer [33] and cervical cancer [16]. Abundant functional investigations in vitro and in vivo indicate that MTDH is a valu-
MiR-98 inhibits the malignant progression of SCCHN

<table>
<thead>
<tr>
<th>Parameters</th>
<th>No. of patients</th>
<th>Relative expression</th>
<th>t value</th>
<th>P-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;59</td>
<td>41</td>
<td>0.509 ± 0.262</td>
<td>1.267</td>
<td>0.209</td>
</tr>
<tr>
<td>≥59</td>
<td>42</td>
<td>0.441 ± 0.220</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>79</td>
<td>0.481 ± 0.245</td>
<td>0.885</td>
<td>0.379</td>
</tr>
<tr>
<td>Female</td>
<td>4</td>
<td>0.371 ± 0.180</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoking history</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>58</td>
<td>0.443 ± 0.231</td>
<td>-1.913</td>
<td>0.059</td>
</tr>
<tr>
<td>No</td>
<td>25</td>
<td>0.552 ± 0.258</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Histological grade</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G3</td>
<td>54</td>
<td>0.479 ± 0.239</td>
<td>0.154</td>
<td>0.878</td>
</tr>
<tr>
<td>G1+G2</td>
<td>29</td>
<td>0.470 ± 0.254</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T classification</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1+T2</td>
<td>46</td>
<td>0.539 ± 0.230</td>
<td>2.767</td>
<td>0.007</td>
</tr>
<tr>
<td>T3+T4</td>
<td>37</td>
<td>0.396 ± 0.238</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical stage</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-II</td>
<td>36</td>
<td>0.605 ± 0.196</td>
<td>4.779</td>
<td>0.000</td>
</tr>
<tr>
<td>III-IV</td>
<td>47</td>
<td>0.376 ± 0.230</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymph node status</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>54</td>
<td>0.572 ± 0.231</td>
<td>5.885</td>
<td>0.000</td>
</tr>
<tr>
<td>N+</td>
<td>29</td>
<td>0.295 ± 0.141</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**NOTE:** *P < .05 was considered to be statistically significance. & G1, G2 and G3 were defined as poorly-differentiated, moderately-differentiated and well-differentiated, respectively.

able tumor biomarker and a potential therapy target in cancers [11, 24]. Our previous study also showed that elevated expression of MTDH protein was tightly correlated with lymph node metastasis and negatively associated with an unfavourable prognosis in patients with SCCHN [17, 38]. MTDH regulated the metastasis of SCCHN via epithelial mesenchymal transition (EMT) in vitro [34]. Therefore, it is worth clarifying upstream and downstream molecules involved in MTDH-mediated malignant alterations in SCCHN.

MicroRNAs (miRNAs) are a class of non-coding small regulated RNAs that have diverse functions in regulating cell activities, including cell proliferation, cell cycle progression, differentiation, invasion, tumor growth and metastasis [5, 30]. Recent studies have shown that miRNAs contribute to carcinogenesis through directly interrupting their targeted mRNA expression or translation, and then serving as tumor suppressors or oncogenes [5, 36]. MicroRNA 98 (miR-98) belongs to the mature let-7 family of miRNAs [22, 23] and is initially found to be down-regulated in leukaemia cell lines [35]. Some reports have suggested that miR-98 expression is associated with diverse malignant behaviours of cancer cells, including growth and chemoresistance [13, 31, 32, 37]. However, the effects of miR-98 on SCCHN cells remain unclear.

miR-98 was putatively to interact with the 3'-untranslated region (3'-UTR) region of MTDH by online prediction algorithms, which may reduce the expression of MTDH mRNA. Therefore, based on our previous study in MTDH and the potential association between miR-98 and MTDH, our present study aims to confirm the exact association between miR-98 and MTDH, and illuminate the role of the interaction between miR-98 and MTDH in the metastasis of SCCHN.

Materials and methods

Cell lines and human tissues

SCCHN Tu686 cell line, established from a primary tongue tumor, was provided by Dr. Zhuo Chen (Emory University Winship Cancer Institute, Atlanta, Georgia, USA). The Nasopharyngeal carcinoma (NPC) 6-10B, 5-8F, and CNE-2 cell lines were purchased from the Cell Center of Central South University, Changsha, China. Tu686 cells and NPC cell lines were maintained in DMEM/F12 and RPMI 1640 medium at 37°C in 5% CO2 atmosphere, which was supplemented with 10% fetal bovine serum (FBS, Hyclone), 100 IU/mL penicillin and 100 IU/mL streptomycin (Gibco).

Two patient cohorts were included in our current investigation. Cohort 1 had 30 paired SCCHN specimens and adjacent noncancerous epithelial tissues, and cohort 2 included 83 SCCHN specimens. All tissues were collected from patients who received surgical therapy at the Department of Otolaryngology Head and Neck Surgery in Xiangya Hospital, Central South University, Changsha, Hunan, China. Patient cohort 1 ranged from January 2010 to October 2013, and cohort 2 ranged from January 2008...
MiR-98 inhibits the malignant progression of SCCHN

Pathological tumor-node-metastasis (TNM) stage was determined according to the 7th American Joint Committee on Cancer staging system in 2010. The main clinicopathological parameters of patient cohorts 1 and 2 are described in detail in Supplementary Table 1 and Table 1, respectively. Patient inclusion criteria of the current study is as follows: no history of radiotherapy or chemotherapy, and primary SCCHN without other malignancies. Informed consent was obtained from all patients before surgery. All experiments were approved by the Research Ethics Committee of Xiangya Hospital, Central South University, Changsha, China.

Follow-up information of patients after surgery was obtained by clinical examination, imaging evaluation, and pathological studies. Overall survival (OS) was calculated from the day of surgery to the date of death. Deaths from other causes were treated as censored cases.

**Quantitative reverse transcription-polymerase chain reaction analysis (qRT-PCR)**

Total RNA was isolated and purified from cells and tissues of SCCHN using the RNeasy Plus Mini Kit (QIAGEN, Germany) according to the manufacturer's instructions. To quantify miR-98 expression, the All-in-One™ miRNA qPCR Detection Kit (GeneCopoeia Inc., USA) was used for reverse transcription and PCR amplification. As to the expression of MTDH mRNA, the High Capacity RNA-to-cDNA Kit and SYBR® Green PCR Master Mix (Applied Biosystems, CA, USA) was used to reverse transcription and PCR amplification. All primers were designed as follows: MTDH primer, forward 5'-GAT GAT GAA TGG TCT GGG TTA AA-3' and reverse 5'-GAC CTT TTG ATC ATC AGG AAT TG-3'; GAPDH primer, forward 5'-TCC AAA ATC AAG TGG GGC GA-3' and reverse 5'-AGT AGA GGC AGG GAT GAT GT-3'. RNA U6 and GAPDH were used as endogenous controls for the detection of miR-98 and MTDH expression, respectively. Expression levels of miR-98 and MTDH were quantified using the methods of 2^ΔΔCt (miR-98/U6, MTDH/GAPDH) or 2^-ΔΔCt (tumor/adjacent noncancerous epithelial tissues) [25].

**SCCHN transfection**

Tu686 and 6-10B cells were transfected with miR-98 mimic or inhibitor (Gene-Pharma Co. Shanghai, China) following the manufacturer's protocol. For MTDH overexpression, a lentiviral vector encoding either MTDH cDNA without its 3'-untranslated regions (3'-UTR) or control eGFP was used (GeneCopoeia Inc., Guangzhou, China) at a multiplicity of infection (MOI) of 50 pfu/cell according to our previous studies [34, 38]. Forty-eight to 72 hours post transfection, transfection efficiency of miR-98 and MTDH was assessed via qRT-PCR or/and western blotting.

**Western blotting**

Whole cell protein extracts were collected and western blot assays were performed as we previously described [19, 34, 38]. In brief, 50-100 μg were separated by 8-12% SDS-PAGE and then transferred onto polyvinylidene difluoride membrane (Millipore). The blotted membranes were then incubated with primary antibodies and subsequently incubated with an HRP-labelled secondary antibody. β-Actin was used as a loading control. Protein densitometry of western blotting bands was quantified by Image J. Details about antibody dilution, incubation time and temperature etc in our study are listed in Supplementary Table 2.

**CCK-8 assay**

All types of SCCHN cells were seeded in a 96-well plate at a concentration of 3000-5000 cells per well. Cells were then maintained at 37°C for 24, 48, 72 and 96 hours after transfection. The cells were treated with CCK-8 for 1 hour at 37°C. The absorbance was determined by a microplate reader at 450 nM. Averages were determined via triplicate experiments.

**Colony formation assay**

Forty-eight hours after transfection, all cells were seeded in a six-well plate at a density of 100 cells per well. After culture for 15 days, clones were fixed with 4% paraformaldehyde for 30 minutes and then stained with crystal violet dye for 5 minutes. Surviving colonies (a colony was defined as > 50 cells) were counted as in our previous study [14].

**Flow cytometry analysis**

Cell cycle distribution and apoptosis of SCCHN cells were examined by flow cytometry analyses, which were performed using the staining...
MiR-98 inhibits the malignant progression of SCCHN

Wounding-healing and transwell invasion assay

The wound-healing and invasion assays have been described previously [18, 34, 38]. For wound healing migration, SCCHN cells that grow to confluence were disrupted with 10-μl pipette tips, which were cultured in medium without serum for another 48 h and photographs were captured under phase-contrast microscope.

For Transwell invasion assay, SCCHN cells were seeded into the upper 24-well Transwell chambers that coated with 200 μl Matrigel at a concentration of 200 μg/ml. SCCHN cells were allowed to invade through the pores under the chemotaxis of 12% FBS for 48-72 h. After the fixation of methanol and stained with crystal violet, invaded cells were counted and photographed under a microscope.

Figure 1. MTDH is directly targeted by miR-98. A. MiRNAs that regulate MTDH mRNA are predicted by the online software TargetScanHuman, and the predicted miR-98 is highlighted by black arrow and black rectangle. B. Putative binding sites of the 3’UTR of MTDH mRNA and miR-98 and the mutant sequence of 3’UTR of MTDH mRNA. C. Tu686 cells that co-transfected with miR-98 mimic, MTDH 3’UTR-WT, or 3’UTR-MU were examined by luciferase reporter assays 48 hours after transfection. NC, negative control. D and F. MTDH mRNA and protein were quantified by qPCR and western blot in Tu686 cells 72 hours after the transfection of miR-98 mimic. E and G. MTDH mRNA and protein were quantified by qPCR and western blot in 6-10B cells 72 hours after the transfection of miR-98 inhibitor. ***$P<0.001$.
MiR-98 inhibits the malignant progression of SCCHN

Luciferase reporter assays

The wild-type and mutated 3'-UTR of the MTDH gene were cloned into the pmirGLO Dual-Luciferase miRNA Target Expression Vector (Promega, USA). Tu686 cells seeded on a 24-well plate and co-transfected with 50 nM of either miR-98 mimics or NC oligos together with 200 ng reporter plasmid including either wild-type or mutant 3'-UTR using Lipofectamine 2000 Reagent (Invitrogen). The relative luciferase activity in each sample was measured using the Dual-Luciferase Reporter Assay System (Promega, USA) 48 hours after transfection.

Statistical analysis

All data were evaluated using IBM SPSS version 13.0. Student’s t test or one-way analysis of variance (ANOVA) test was performed to analyse the significance of differences between samples obtained from three independent experiments. Clinical associations between miR-98 and clinicopathological parameters were compared by Student’s t test. Survival analyses were undertaken using the Kaplan-Meier method, and curves were compared by the log-rank test. The quantitative data in this study were expressed as the means ± standard deviation (SD). Differences were considered significant at the value of \( P < 0.05 \).

Results

MTDH is directly targeted by miR-98

Our recent study suggested that elevated MTDH was an unfavourable factor in patients with SCCHN, and that MTDH regulated the metastasis of SCCHN in vitro [17, 34, 38]. To investigate how MTDH is aberrantly regulated by miRNAs in SCCHN, miR-98 is predicted to possibly bind to the 3'-UTR region at the position from 1870 to 1877 of MTDH mRNA, according to the results based on the online prediction algorithm of TargetScanHuman (Figure 1A and 1B). Therefore, luciferase reporter assays were applied to determine whether MTDH could be directly modulated by miR-98. Luciferase reporter plasmids encoding the wild type (WT) or mutant (MU) 3'-UTR domain of MTDH mRNA were designed (Figure 1B), and then miR-98 mimic was co-transfected with the reporter plasmid into SCCHN Tu686 cells. As shown in Figure 1C, luciferase activities in Tu686 cells co-transfected with MTDH 3'-UTR-WT and miR-98 mimic were significantly lower than those cells co-transfected with MTDH 3'-UTR-WT and NCs \( (P < 0.01) \). However, no significant differences in luciferase activities were observed between cells co-transfected with MTDH 3'-UTR-MU and NCs and cells co-transfected with MTDH 3'-UTR-MU and miR-98 mimic \( (P > 0.05) \). These data meant that miR-98 could regulate the expression of MTDH by directly binding to the 3'-UTR region of MTDH mRNA. Furthermore, qPCR and western blot analyses were performed after Tu686 cells were successfully transfected with miR-98 mimic (Supplementary Figure 1B). Our results demonstrated that up-regulation of miR-98 significantly reduced both mRNA and protein expression of MTDH (Figure 1D and 1F). Conversely, down-regulation of miR-98 in SCCHN 6-10B cells via miR-98 inhibitor contributed to the elevation of both mRNA and protein.

Figure 2. MiR-98 expression in SCCHN and its clinical significance. (A and B) Relative individual miR-98 expression was quantified by qPCR in patient cohort 1 comprising 30 patients with SCCHN (A), compared with corresponding adjacent noncancerous epithelial tissue (B). (C) Survival analysis was performed on patient cohort 2 comprising 83 patients with SCCHN according to the expression of miR-98. Data are shown as mean ± SD.
MiR-98 inhibits the malignant progression of SCCHN

A

B

E

C

D

F

OD 450 values

OD 450 values

Cell cycle 

Number of colonies

Number of colonies

Rate of apoptosis (%)
of MTDH (Supplementary Figure 1C, Figure 1E and 1G). Taken together, our results obviously show that miR-98 could directly combine the 3′-UTR domain of MTDH and then regulate its expression.

**Decreased expression of miR-98 correlates with aggressive progression and poor survival in patients with SCCHN**

To confirm the associations between miR-98 and clinical parameters of patients with SCCHN, qPCR was used to detect its expression in two cohorts of patients with SCCHN in our study. In patient cohort 1, qPCR data showed that miR-98 expression was significantly decreased in SCCHN tissues (Figure 2A and 2B). Due to the lack of prognostic information in patient cohort 1, we used patient cohort 2, which was consisted of 83 SCCHN patients with intact prognostic information, to validate the associations between miR-98 expression and patient prognosis. In our study, patients with SCCHN were divided into two groups, the high-miR-98 group (n = 41) and the low-miR-98 group (n = 42), in which miR-98 expression was greater than or less than the median value in the 83 patients with SCCHN, respectively. As summarised in Table 1 via Student’s t test, miR-98 expression levels were inversely correlated with T classification (P = 0.007), advanced clinical stages (P < 0.001) and lymph node metastasis (P < 0.001). However, no significant associations were found between miR-98 expression and other clinical parameters, including age (P = 0.209), gender (P = 0.379), smoking history (P = 0.059) and tumor histological grade (P = 0.878). Moreover, the Kaplan-Meier method and a log-rank test were applied to determine the prognostic value of miR-98 in this patient cohort. Our data showed that patients in the low-miR-98 group had significantly shorter overall survival time than that in patients with a high-miR-98 expression (Figure 2C, P = 0.006). Taken together, the above data show us that decreased miR-98 expression is tightly correlated with aggressive phenotypes and a poorer prognosis in patients with SCCHN.

**MiR-98 inhibits the proliferation of SCCHN cells in vitro**

To further investigate the role of miR-98 in the tumorigenesis of SCCHN, mimic and inhibitor of miR-98 were designed to change its level in SCCHN cell lines with different expression of miR-98 (Supplementary Figure 1A). As shown in Supplementary Figure 1B, mimic successfully upregulated miR-98 expression by 10.8 ± 1.5-fold in Tu686 cells. At the same time, miR-98 inhibitor decreased its expression to a fold of 0.28 ± 0.4 in 6-10B cells (Supplementary Figure 1C). Subsequently, growth abilities of both Tu686 and 6-10B cells were examined by CCK-8 and plate colony formation assays. We found that miR-98 upregulation impeded the proliferation of Tu686 cells at day 3 and day 4 in vitro, and Tu686 cells also formed smaller and fewer colonies at day 15 after miR-98 upregulation (Figure 3A and 3C). Conversely, miR-98 downregulation promoted the proliferation of 6-10B cells at day 3 and day 4 in vitro, and led to more and larger colonies once miR-98 was inhibited at day 15 (Figure 3B and 3D).

Importantly, flow cytometry assays displayed that miR-98 overexpression in Tu686 induced cell cycle arrest at the G0/G1 phase and decreased in G2/M phase (Figure 3E). As to apoptosis, Tu686 cells transfected with miR-98 mimic showed increased apoptotic rate (Figure 3F). Together, these results suggest that miR-98 overexpression could suppress the proliferation of SCCHN via promoting cell cycle progression and apoptosis.

**MiR-98 impedes in the migration and invasion of SCCHN cells in vitro**

To further investigate the role of miR-98 in the migratory and invasive capacity of SCCHN, wound-healing assays and Transwell assays were employed. Our data clearly showed that the wound healing-ability of Tu686 cells transfected with miR-98 mimics significantly slowed down at 48 hours (Figure 4A, P < 0.05), and Tu686 cells transfected with miR-98 mimics invaded through the Transwell membrane were...
MiR-98 inhibits the malignant progression of SCCHN

also significantly reduced (Figure 4C, P < 0.05). On the other hand, miR-98 inhibition in 6-10B cells correspondingly led to enhanced wound-healing ability at 48 hours (Figure 4B, P < 0.05) and increased the cell numbers that passed through the Transwell membrane at 48 hours (Figure 4D, P < 0.05). To explore the mechanism, we found that miR-98 upregulation increased the expression of E-cadherin and decreased the expression of vimentin in Tu686...
MiR-98 inhibits the malignant progression of SCCHN

2562 Am J Cancer Res 2017;7(12):2554-2565

Supplementary Figure 2A, whereas miR-98 inhibition reduced the expression of E-cadherin and elevated the expression of vimentin in 6-10B cells (Supplementary Figure 2B). As E-cadherin and vimentin are canonical epithelial and mesenchymal biomarkers of epithelial-mesenchymal transition (EMT), these data indicate that miR-98 plays a critical role in the migration and invasion of SCCHN via regulating the EMT process.

MTDH is partially involved in the invasion of SCCHN caused by miR-98

We have demonstrated that decreased miR-98 is responsible for the malignant progression of SCCHN and identified MTDH as a direct target of miR-98. Therefore, we studied the actual functional involvement of MTDH in the following rescue experiments. SCCHN Tu686 cells were transfected with miR-98 mimic and MTDH cDNA without its 3'-UTR region or corresponding empty vectors, and transfection efficiency was evaluated by western blot assays (Supplementary Figure 3). Subsequently, our assays showed that MTDH overexpression partially attenuated the inhibition of migration (Figure 5A and 5B) and invasion (Figure 5C and 5D) caused by miR-98 in Tu686 cells. Consistent with the phenotype alterations in these rescue experiments, elevated expression of E-cadherin and inhibited expression of Vimentin following miR-98 overexpression could also be reversed by MTDH overexpression (Supplementary Figure 3). However, colony formation assays indicated that ectopic overexpression of MTDH
displayed no obvious effects on cell proliferation in Tu686 cells transfected with miR-98 mimic (Figure 5E and 5F). Collectively, our data show that MTDH could be at least partially implicated in the miR-98-dependent regulation of the invasion of SCCHN.

Discussion

MTDH, as an oncogene, functions widely in numerous malignant behaviours in cancer cells, such as unlimited proliferation, invasion and migration [4, 11]. Our previous study indicated that MTDH was overexpressed in SCCHN tissues and negatively correlated with the prognosis of patients with SCCHN [17]. Moreover, MTDH overexpression enhanced the migratory and invasive ability of SCCHN cells via promoting the occurrence of EMT [17, 34, 38]. Consistent with reports from other groups, MTDH gene copy also amplify in SCCHN patients [2]. To further answer the question of how MTDH is abnormally regulated in cancer, we used online algorithms to predict miRNAs that potentially regulate MTDH. As expected, numerous miRNAs, in which miRNA-375, miRNA-145 and miRNA-137 have been predicted and also confirmed to regulate MTDH in recent publications [6, 8, 9]. Therefore, we focused on evaluating the potential regulation of miR-98 on MTDH, which has not been studied. Our study initially confirmed that miR-98 could directly interact with the 3’-UTR region of MTDH, and then hinder the protein translation of MTDH.

Consistent with reports in other solid tumors, including oesophageal squamous cell carcinoma [12], oral squamous cell carcinoma [27] and non-small-cell lung cancer [21], the expression of miR-98 was also down-regulated in SCCHN, displaying an inverse expression style with its target gene MTDH [17, 34]. Two patient cohorts were used in our study to find the associations between miR-98 expression and clinicopathological parameters, which obviously indicated that decreased miR-98 expression was tightly correlated with clinical stages and lymph node metastasis in patients with SCCHN. Especially in patient cohort 2, with intact clinical information, we found that SCCHN patients with decreased miR-98 expression were closely associated with a poorer survival status. The clinical significance of miR-98 has been scarcely investigated, except for in the case of melanoma, in which low miR-98 expression was also found to be associated with poor survival [13]. Consistent with the results found in tissues, our in vitro experiments demonstrated that up- or down-regulation of miR-98 could influence the capacities of proliferation, migration and invasion of SCCHN cells. Altogether, these data indicate the importance of miR-98 in SCCHN progression and metastasis after surgical resection.

MiRNAs exert their functions by focusing on different targets including oncogenes and/or suppressors. Specific miRNA can simultaneously target multiple genes [5]. Available evidence demonstrates that miR-98 can target the following oncogenes or suppressors in different tumors: ITGB3 [21], caspase-3 [15], IL-6 [13, 29], HMGA2 [32], ALK4 [26] and MMP11 [26]. In our present study, we found that miR-98 could directly bind to the 3’-UTR region of MTDH mRNA, accelerate the degradation of MTDH mRNA, and eventually hinder the expression of MTDH protein. Also, miR-98 and MTDH have an opposite expression style in SCCHN, in which miR-98 is decreased and MTDH is overexpressed in SCCHN [17]. These data indicate that MTDH is a direct downstream target of miR-98. Together with the target of MTDH, we found that repressed expression of miR-98 in tumors led to abnormally elevated expression of these oncogenes and then promoted cancer progression. In our study, restored MTDH expression in miR-98 overexpressing cells partially abolished the inhibition of malignant behaviours caused by miR-98, which indicates that MTDH is at least partially implicated in the anti-tumor effects of miR-98, although we cannot exclude the possibility that other gene targets of miR-98 may be also involved in this process.

Metastasis leads to the dissemination of primary tumor cells and then seeding at distant locations to form secondary tumors. The prerequisite of metastasis demands cancer cells to separate from the primary site and acquires enhanced migratory and invasive abilities. EMT has a critical role in the initiation of metastasis [3]. Recently, we found that MTDH was correlated with the promotion of EMT and metastasis [17, 34]. Our current study also demonstrated that miR-98 could regulate the expression of epithelial marker E-cadherin and mesenchymal marker Vimentin, and subsequently participated in processes of EMT and metastasis. Ectopic expression of MTDH in Tu686 cells after miR-
MiR-98 inhibits the malignant progression of SCCHN

98 mimic transfection restored the changes of EMT and metastasis caused by miR-98, which indicates that MTDH and miR-98 can form a miR-98/MTDH axis pathway and together to influence the metastasis and EMT of SCCHN.

We have to mention that the mechanisms by which miR-98/MTDH axis contributes to the EMT and metastasis of SCCHN are still waiting for investigation. Available evidence indicates that MTDH facilitates the carcinogenesis via remodelling diverse signalling pathways including NF-kB, PI3K/Akt and Wnt/β-catenin pathways etc [11]. Among these pathways, PI3K/Akt pathway plays a central role in the regulation of cell proliferation, survival and metastasis [20]. Our previous studies have emphasised the importance of PI3K/Akt in the MTDH-mediated changes in SCCHN [34, 38], which hints us that miR-98/MTDH axis and downstream PI3K/Akt may function together in the progression of SCCHN. However, the detailed signalling pathways underlying the effects of miR-98/MTDH axis on the EMT and metastasis are worth of systemic and deep study in the future.

In summary, our study indicates that repression of miR-98 leads to elevated MTDH, which in turn enhances the expression of effectors such as EMT molecules, and finally promotes the progression of SCCHN. MiR-98 serves as a suppressor miRNA and a potential therapeutic target for patients with SCCHN. However, in-depth molecular mechanism study and in vivo animal models are urgent and indispensable to further clarify the function of miR-98 in SCCHN.

Acknowledgements

This study was funded by grants from the National Natural Science Foundation of China (Nos. 81772903, 81773243, 81202128, 8160111661, 81372426, 8160102702 and 81472696), and the Natural Science Foundation of Hunan Province (No. 2015JJ3137).

Informed consent was obtained from all individual participants included in the study.

Disclosure of conflict of interest

None.

Address correspondence to: Yong Liu and Xin Zhang, Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha 410008, Hunan, People’s Republic of China. E-mail: liuyongent@csu.edu.cn (YL); xinzhang@csu.edu.cn (XZ)

References

MiR-98 inhibits the malignant progression of SCCHN


MiR-98 inhibits the malignant progression of SCCHN

**Supplementary Table 1.** Clinicopathological features of patient cohort 1

<table>
<thead>
<tr>
<th>Parameters</th>
<th>No. of patients</th>
<th>Percentage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 55</td>
<td>19</td>
<td>63.3</td>
</tr>
<tr>
<td>≥ 55</td>
<td>11</td>
<td>36.7</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>28</td>
<td>93.3</td>
</tr>
<tr>
<td>Female</td>
<td>2</td>
<td>0.7</td>
</tr>
<tr>
<td>Smoking history</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>28</td>
<td>93.3</td>
</tr>
<tr>
<td>No</td>
<td>2</td>
<td>0.7</td>
</tr>
<tr>
<td>Histological grade</td>
<td></td>
<td></td>
</tr>
<tr>
<td>G1</td>
<td>21</td>
<td>70.0</td>
</tr>
<tr>
<td>G2+G3</td>
<td>9</td>
<td>30.0</td>
</tr>
<tr>
<td>T classification</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1+T2</td>
<td>14</td>
<td>46.7</td>
</tr>
<tr>
<td>T3+T4</td>
<td>16</td>
<td>53.3</td>
</tr>
<tr>
<td>Clinical stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-II</td>
<td>13</td>
<td>43.3</td>
</tr>
<tr>
<td>III-IV</td>
<td>17</td>
<td>56.7</td>
</tr>
<tr>
<td>Lymph node status</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>21</td>
<td>70.0</td>
</tr>
<tr>
<td>N+</td>
<td>9</td>
<td>30.0</td>
</tr>
</tbody>
</table>

**Supplementary Table 2.** Antibodies

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Company</th>
<th>No.</th>
<th>Source</th>
<th>Working concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>E-cadherin</td>
<td>Proteintech Group Inc, USA</td>
<td>20874-1-AP</td>
<td>Rabbit polyclonal antibody</td>
<td>1:1200</td>
</tr>
<tr>
<td>Vimentin</td>
<td>Proteintech Group Inc, USA</td>
<td>10366-1-AP</td>
<td>Rabbit polyclonal antibody</td>
<td>1:500</td>
</tr>
<tr>
<td>MTDH</td>
<td>Proteintech Group Inc, USA</td>
<td>13860-1-AP</td>
<td>Rabbit polyclonal antibody</td>
<td>1:600</td>
</tr>
<tr>
<td>MTDH</td>
<td>Invitrogen, USA</td>
<td>40-6500</td>
<td>Rabbit polyclonal antibody</td>
<td>1:500</td>
</tr>
<tr>
<td>β-actin</td>
<td>Beyotime, China</td>
<td>AA128</td>
<td>Mouse monoclonal antibody</td>
<td>1:2000</td>
</tr>
</tbody>
</table>

**Supplementary Figure 1.** MiR-98 expression in SCCHN cells. A. MiR-98 expression in four SCCHN cell lines was quantified by qPCR. B. MiR-98 expression was levelled by qPCR 48 hours after Tu686 cells were transfected with miR-98 mimic. C. MiR-98 expression was assayed by qPCR in 6-10B cells 48 hours after the transfection of miR-98 inhibitor. Data are shown as mean ± SD. ***P < 0.001.
MiR-98 inhibits the malignant progression of SCCHN

Supplementary Figure 2. Effects of miR-98 on the EMT change in SCCHN cells. EMT markers E-cadherin and Vimentin were plotted by western blotting 72 hours after miR-98 mimic transfected in Tu686 cells (A) and miR-98 inhibitor transfected in 6-10B cells (B).

Supplementary Figure 3. MTDH is involved in the EMT process mediated by miR-98. Tu686 cells were singly transfected with miR-98 mimic or MTDH cDNA, and transfected with the combination of both miR-98 mimic and MTDH cDNA. EMT markers and MTDH were assayed by western blotting 72 hours after transfection.